Replies to post #92741 on Biotech Values

[DewDiligence]

Any liability Teva might incur from its own at-risk launches would pale compared to the losses it would suffer if a US generic for Copaxone reached the market in the next few years.

[genisi]

Teva at risk launches

On Lotrel - Par's settlement with NVS is a significant positive for Teva, which has the only generic on the market (except for Sandoz's authorized).
On Protonix - Wyeth's preliminary injunction was rejected and Teva's obviousness arguments might even win the litigation but even if Teva loses, the risk is much lower than it seemed (probably single not treble damages).
Gemzar is a potential for at risk launch by Teva.

[DewDiligence]

Generic-Protonix update: Teva could conceivably be liable for treble
damages. A jury in the US District Court just found that the Protonix
CoM patent (4,758,579) is non-obvious and hence enforceable. Teva
launched its generic in Dec 2007 (#msg-25538409) after the court
denied Wyeth a temporary injunction (#msg-22653920). When a
a brief attempt to settle the case failed, Wyeth launched an AG in
Jan 2008 (#msg-26375070); how the AG ultimately affects the
award of damages remains to be seen. Meanwhile, PFE’s pediatric
extension of the patent at issue in the lawsuit expires in Jan 2011.

http://www.reuters.com/article/idCNN2321927120100423

›Pfizer Wins Protonix Patent Case vs Teva

Fri Apr 23, 2010 5:23pm EDT

* Jury finds Protonix patent infringed by Teva

* Some legal issues in case to be decided by judge

NEW YORK, April 23 (Reuters) - A New Jersey jury handed a victory to Pfizer Inc <PFE> on Friday, ruling that the patent on its Protonix acid reflux drug is valid and infringed by Teva Pharmaceutical Industries, which has been selling a generic version of the drug since 2007, the companies said.

The jury in the U.S. District Court for New Jersey rejected allegations by Teva and India's Sun Pharmaceuticals Industries <SUN.BO> that the patent on the widely used drug was obvious and should be declared invalid, Pfizer said.

The original patent on Protonix, known chemically as pantoprazole, is held by Swiss drugmaker Nycomed and was licensed to Wyeth, which is now owned by Pfizer. Nycomed and Wyeth filed their patent infringement lawsuit against Teva and Sun in May 2004.

"We are pleased with the jury's findings," Pfizer said in a statement. "The jury held that the patent was not invalid, rejecting allegations by several generic companies that the patent was obvious."

Pfizer, the world's largest drugmaker, and Teva, the world's biggest maker of generic medicines, said there were still legal issues to be decided by the judge presiding over the case.

"A decision by the District Court judge independent of today's jury verdict would be sufficient to invalidate the patent," Israel-based Teva said in a statement.

A final decision could be appealed, Pfizer said.

"If we are successful at the end of this process, we will be seeking the full measure of our damages," Pfizer spokesman Christopher Loder said.

He declined to discuss the extent of damages Pfizer might seek. However, in similar cases when a product's patent has been found to be infringed the company holding the patent may seek triple damages on lost sales and reimbursement of legal fees.‹

[DewDiligence]

I…question whether some of the at-risk launches by Teva might eventually be litigated in the oppositions’ favor.

In the case of Protonix, that was a $2.15B question :- )